Could a drug combo free kidney transplant patients from lifelong pills?
Disease control
Ongoing
This phase 2 study tests whether a drug called TCD601 (siplizumab), combined with donor bone marrow cells and mild chemotherapy, can train the immune system to accept a new kidney without needing lifelong anti-rejection drugs. The trial involves 18 adults receiving a kidney from …
Phase: PHASE2 • Sponsor: ITB-Med LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC